Clever, Personable, and Unconventional: Acutus Medical Reaches EU MDR Milestone in Sale to Medtronic

Clever, Personable, and Unconventional: Acutus Medical Achieves EU MDR Submission Milestone What’s the Buzz About? Imagine a world where heart arrhythmias can be diagnosed and treated in a way that is revolutionary and groundbreaking. That world is not as far off as you may think, thanks to Acutus Medical, Inc. This innovative company, focused on…

Read More

Revolutionizing Prosthetic Care: How the Protez Foundation and OneStep Partnership Connects Patients from 5,000 Miles Away

US Clinicians Utilize OneStep App to Extend Care to Soldiers in Ukraine New York and Minneapolis, Dec. 21, 2022 Protez Foundation, a non-profit organization dedicated to helping Ukrainian amputees, has partnered with OneStep to revolutionize the way prosthetic patients receive care. Through the use of the OneStep app, clinicians in the US are able to…

Read More

Datacubed Health, a Sterling Partners Portfolio Company, Soars with 150% Year-Over-Year Growth

Datacubed Health, a Sterling Partners Portfolio Company, Achieves Substantial Year-Over-Year Growth Brooklyn, New York, Dec. 20, 2022 (GLOBE NEWSWIRE) — Datacubed Health (“Datacubed”), a digital health technology company that supports hybrid and decentralized clinical trials, and Sterling Partners (“Sterling”), a prominent investment management firm, announced December 20, 2022, substantial year-over-year growth. Datacubed Health, a leading…

Read More

Revolutionizing Nuclear Imaging: Positron Corporation’s Groundbreaking Affinity PET-CT 4D Device Set to Make Waves in Clinical Study

Niagara Falls, NY, Dec. 20, 2022 (GLOBE NEWSWIRE) — Positron Corporation (“Positron” or the “Company”) (OTC: POSC), a nuclear medicine PET imaging systems and clinical services company, is pleased to announce the Company’s collaboration with Dr. Bober and Ochsner Health, the largest non-profit, academic healthcare system operating in Louisiana, for the clinical study of Positron’s…

Read More

Journey Medical Corporation Reveals Promising Comparative Pharmacokinetic (PK) Data for DFD-29: A Step Towards Improved Medical Treatment

Journey Medical Corporation Announces Positive Comparative Phar… Phase 3 Registrational Studies Progressing Smoothly SCOTTSDALE, Ariz., Dec. 20, 2022 (GLOBE NEWSWIRE) — Journey Medical Corporation (NASDAQ: DERM) (“Journey Medical”), a commercial-stage biopharmaceutical company focused on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions, today announced positive PK comparability data. Exciting news…

Read More